AbbVie, Samsung Bioepis in deal, Humira biosimilar US release in 2023

AbbVie Inc said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.

This is the second deal AbbVie has signed over the past year as it tries to safeguard patents on Humira, which is the world’s top-selling prescription medicine.

The drug, which treats rheumatoid arthritis, raked in $18.43 billion in sales last year and accounted for nearly two-thirds of AbbVie’s net revenue.

While terms of the deal were undisclosed, AbbVie said it will make no payments to Samsung Bioepis and the three companies agreed to dismiss all pending lawsuits.

Even if multiple Humira biosimilars are delayed from the market until 2023, this can be “more than offset” by a steeper sales decline for Humira, BMO Capital Markets analyst Alex Arfaei said.

Arfaei noted this is increasingly likely given the U.S. Food and Drug Administration’s encouraging stance on the approval of biosimilar drugs and fewer chances of drugmakers negotiating with insurers to gain preferred coverage of their drugs over rivals.

Samsung Bioepis is partnered with Biogen to market the drug in Europe and Merck & Co to market it in the United States.

Biogen expects to launch the biosimilar, Imraldi, in Europe in mid-October this year.

In September, Amgen Inc reached a similar settlement with AbbVie to delay the U.S. launch of its cheaper biosimilar to Humira until Jan. 31, 2023.

Shares of AbbVie, which has been focusing on developing cancer drugs to sustain long-term growth, have been under pressure in recent months hurt by a failed trial of an experimental lung cancer treatment, Rova-T.